Welcome to our dedicated page for United Therapeutics news (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics stock.
United Therapeutics Corporation (UTHR) is a pioneering biotechnology company dedicated to developing and commercializing innovative products that address unmet medical needs for patients with chronic and life-threatening conditions. The company's core business revolves around the creation of treatments for pulmonary arterial hypertension (PAH), a rare and progressive disease characterized by high blood pressure in the lungs' arteries. United Therapeutics' therapies predominantly focus on the prostacyclin pathway, with many treatments based on the molecule treprostinil.
With five approved products on the market, United Therapeutics is relentless in its mission to deliver 'medicines for life.' The company's long-term vision includes providing an unlimited supply of transplantable organs to those in need. Employees collaborate across the United States, Europe, and Asia to achieve this ambitious goal.
In addition to its focus on PAH, the company is also dedicated to researching and developing treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. United Therapeutics markets a pediatric oncology drug, but its primary focus remains on advancing therapeutics for PAH.
United Therapeutics has seen significant achievements in recent years, continually pushing the boundaries of medical science. Their financial condition remains robust, driven largely by sales within the United States. The company is actively engaged in various partnerships and projects aimed at enhancing their therapeutic offerings and expanding their global footprint.
United Therapeutics Corporation (Nasdaq: UTHR) will report its first quarter 2023 financial results on May 3, 2023, before the market opens. A public webcast will follow at 9:00 a.m. Eastern Time, accessible via the company's website. As a public benefit corporation, United Therapeutics is committed to addressing unmet medical needs and enhancing the availability of transplantable organs through innovative pharmaceutical therapies. The company emphasizes its mission-driven approach, aiming to benefit both patients and stakeholders.
Forward-looking statements regarding their future innovations highlight potential risks and uncertainties that may affect actual results. For detailed information, interested parties can refer to their filings with the Securities and Exchange Commission.
United Therapeutics (NASDAQ: UTHR) has announced that it will present research from its development portfolio at two significant medical conferences: the ISHLT 43rd Annual Meeting and ATS International Conference, both scheduled for April and May 2023, respectively. Key presentations will include findings from the phase 4 ARTISAN study aimed at treating pulmonary arterial hypertension through enhanced treprostinil administration and results from the EXPEDITE study highlighting the positive effects of Remodulin induction prior to Orenitram therapy. The data presented will focus on improving patient outcomes, emphasizing geographical disparities in PAH care, and showcasing the company's innovative xenotransplantation research.
United Therapeutics Corporation (Nasdaq: UTHR) announced that Dr. Martine Rothblatt, CEO and Chairperson, will present an update on the company's business during a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference. The session is scheduled for
United Therapeutics Corporation (Nasdaq: UTHR) announced that President and COO Michael Benkowitz will provide a business overview at the Cowen 43rd Annual Health Care Conference in Boston on March 7, 2023, from 9:10 a.m. to 9:40 a.m. EST. The session will be accessible via a live webcast on the company's website and an archived version will be available for 90 days post-event. United Therapeutics, as a public benefit corporation, focuses on innovative pharmaceutical therapies and technologies for transplantable organs, aiming to meet the medical needs of patients.
United Therapeutics Corporation (Nasdaq: UTHR) reported a record revenue of $1.94 billion for the year ending December 31, 2022, marking an 18% increase from 2021. The fourth quarter revenues reached $491.5 million, an 18% rise year-over-year. Key products, especially Tyvaso, saw significant growth, with sales increasing 46% in Q4 and 44% for the full year. The company aims to double its revenue to a $4 billion run rate by 2025, driven by ongoing patient growth and pivotal clinical data expected for Tyvaso and ralinepag.
United Therapeutics Corporation (Nasdaq: UTHR) will announce its fourth quarter and full year 2022 financial results on February 22, 2023, before market opening. A public webcast will follow at 9:00 a.m. Eastern Time on the same day, accessible on the company's website. As a pioneering public benefit corporation, United Therapeutics focuses on developing novel pharmaceutical therapies and technologies to enhance organ transplant availability for patients. The company emphasizes its mission to address unmet medical needs through innovation and stakeholder benefit.
United Therapeutics Corporation (UTHR) has announced that Dr. Martine Rothblatt, CEO, will provide a business overview during a fireside chat at the 41st J.P. Morgan Healthcare Conference in San Francisco. The event is scheduled for Monday, January 9, 2023, from 1:30 p.m. to 2:10 p.m. PST. It will be accessible via live webcast on the United Therapeutics website, with an archived version available 24 hours post-event. United Therapeutics strives to innovate for unmet medical needs as a public benefit corporation.
FAQ
What is the current stock price of United Therapeutics (UTHR)?
What is the market cap of United Therapeutics (UTHR)?
What does United Therapeutics Corporation specialize in?
How many approved products does United Therapeutics have?
What is pulmonary arterial hypertension?
What is the company's long-term mission?
Where are United Therapeutics' employees located?
What molecule forms the basis of many of the company's treatments?
Does United Therapeutics market any oncology drugs?
What drives United Therapeutics' financial condition?
Is United Therapeutics involved in partnerships?
What are the latest news and developments from United Therapeutics?
